ATE486962T1 - Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon - Google Patents
Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davonInfo
- Publication number
- ATE486962T1 ATE486962T1 AT05737007T AT05737007T ATE486962T1 AT E486962 T1 ATE486962 T1 AT E486962T1 AT 05737007 T AT05737007 T AT 05737007T AT 05737007 T AT05737007 T AT 05737007T AT E486962 T1 ATE486962 T1 AT E486962T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- receptor protein
- salt
- screening
- new ligand
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000012216 screening Methods 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004131726 | 2004-04-27 | ||
| PCT/JP2005/008403 WO2005103291A1 (ja) | 2004-04-27 | 2005-04-26 | Gタンパク質共役型レセプタータンパク質の新規リガンドとその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE486962T1 true ATE486962T1 (de) | 2010-11-15 |
Family
ID=35196997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05737007T ATE486962T1 (de) | 2004-04-27 | 2005-04-26 | Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7833722B2 (de) |
| EP (1) | EP1741792B1 (de) |
| JP (1) | JP4685767B2 (de) |
| AT (1) | ATE486962T1 (de) |
| DE (1) | DE602005024537D1 (de) |
| WO (1) | WO2005103291A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗-vegf抗體 |
| JP5851838B2 (ja) | 2008-10-22 | 2016-02-03 | ジェネンテック, インコーポレイテッド | 軸索変性の調節 |
| US8460862B2 (en) * | 2009-03-11 | 2013-06-11 | Marker Gene Technologies | Enzyme substrates for visualizing acidic organelles |
| EP2567698B1 (de) | 2011-09-07 | 2014-02-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | GPR-17-Agonisten und Screening-Assay |
| TWI754702B (zh) | 2016-12-28 | 2022-02-11 | 德商Ucb製藥有限公司 | (氮雜)吲哚-和苯並呋喃-3-磺醯胺類 |
| TWI857957B (zh) | 2018-06-19 | 2024-10-11 | 德商Ucb製藥有限公司 | 吡啶基及吡基-(氮)吲哚磺醯胺 |
| EP3584244A1 (de) | 2018-06-20 | 2019-12-25 | UCB Pharma GmbH | Substituierte alkoxypyridinylindolsulfonamide |
| WO2020254289A1 (en) | 2019-06-17 | 2020-12-24 | Ucb Pharma Gmbh | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis |
| GB2700773A (en) | 2024-05-23 | 2026-03-11 | Pheno Therapeutics Ltd | Compounds |
| GB2701173A (en) | 2024-05-23 | 2026-04-22 | Pheno Therapeutics Ltd | Compounds |
| GB2642355A (en) | 2024-07-05 | 2026-01-07 | Pheno Therapeutics Ltd | Polymorphs |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2118372T3 (es) | 1992-11-17 | 1998-09-16 | Icos Corp | Nuevos receptores siete transmembrana v28. |
| US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| GB0003902D0 (en) | 2000-02-18 | 2000-04-05 | Glaxo Group Ltd | Assay |
| AU2001244205A1 (en) | 2000-03-14 | 2001-09-24 | Bayer Aktiengesellschaft | Regulation of human p2y-like gpcr protein |
| AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| US20050118639A1 (en) | 2002-02-22 | 2005-06-02 | Takeda Chemical Industries, Ltd | Method of determining ligand |
| US20040176344A1 (en) * | 2004-04-06 | 2004-09-09 | Rooney Roberta Nora Malone | Method to treat patients with amyotrophic lateral sclerosis and the like |
-
2005
- 2005-04-26 DE DE602005024537T patent/DE602005024537D1/de not_active Expired - Lifetime
- 2005-04-26 EP EP05737007A patent/EP1741792B1/de not_active Expired - Lifetime
- 2005-04-26 AT AT05737007T patent/ATE486962T1/de not_active IP Right Cessation
- 2005-04-26 JP JP2006512670A patent/JP4685767B2/ja not_active Expired - Fee Related
- 2005-04-26 WO PCT/JP2005/008403 patent/WO2005103291A1/ja not_active Ceased
- 2005-04-26 US US11/587,631 patent/US7833722B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005103291A1 (ja) | 2005-11-03 |
| DE602005024537D1 (de) | 2010-12-16 |
| EP1741792B1 (de) | 2010-11-03 |
| JPWO2005103291A1 (ja) | 2008-03-13 |
| EP1741792A1 (de) | 2007-01-10 |
| JP4685767B2 (ja) | 2011-05-18 |
| US7833722B2 (en) | 2010-11-16 |
| EP1741792A4 (de) | 2008-11-05 |
| US20080248041A1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1479768A4 (de) | Neues screening-verfahren | |
| ATE486962T1 (de) | Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon | |
| TW200531692A (en) | Aryl aniline derivatives as β2 adrenergic receptor agonists | |
| ATE349434T1 (de) | Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten | |
| ATE446294T1 (de) | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten | |
| EA200600049A1 (ru) | Способы получения 3 - бензазепинов | |
| MA29088B1 (fr) | Composes d'indazole-carboxamide. | |
| BR0207390A (pt) | Compostos, composições farmacêuticas e métodos de tratatamento de doença associada a ativação e a ativação do grupo i mg1ur | |
| BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
| WO2005030678A3 (en) | AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS | |
| DE60312474D1 (de) | 5-ht3-rezeptorantagonisten und verwendungsverfahren | |
| WO2005000875A3 (en) | Compositions and methods comprising a ligand of chemerin receptor | |
| BRPI0409562A (pt) | tratamento de condições envolvendo placas amilóides | |
| FR2888937B1 (fr) | Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes | |
| EP1619499A4 (de) | Neues screening-verfahren | |
| ATE482931T1 (de) | Somatostatinrezeptor-1- und/oder -4-selektive agonisten und antagonisten | |
| EP1584925A4 (de) | Neues screening-verfahren | |
| ATE405827T1 (de) | Screening-verfahren | |
| WO2003082320A1 (fr) | Nouveau procede de criblage | |
| EP1617216A4 (de) | Neues screening-verfahren | |
| WO2004096855A3 (en) | Methods utilising g-protein coupled receptor 54 | |
| ATE447586T1 (de) | Fprl1-liganden und deren verwendung | |
| DE60321443D1 (de) | Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung | |
| SE0101856D0 (sv) | Galanin receptor agonist | |
| WO2007044940A3 (en) | Antibody against a peptide derived from human mutant lamin a protein and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |